Reversible HER2 antibody-drug conjugate–induced ocular toxicity-Reference-Cited by-同舟云学术

Reversible HER2 antibody-drug conjugate–induced ocular toxicity

Published:2021-03 Issue: Volume: Page:
ISSN:0008-4182
Container-title:Canadian Journal of Ophthalmology
language:en
Short-container-title:Canadian Journal of Ophthalmology

Author:

Sharma Anushree,Riaz Kamran M.^ORCID,Gill Mohsain S.^ORCID,Patnaik Amita,Ulahannan Susanna V.^ORCID,Wang Judy S.^ORCID,Gombos Dan S.,Ang Qiuqing,Cicic Dragan,Bergonio Gregory R.,Zhang Cong,Wirostko Barbara M.

Publisher

Elsevier BV

Subject

Ophthalmology,General Medicine

Reference26 articles.

1. Tissue-based map of the human proteome;Uhlen;Science,2015

2. HER story: the next chapter in HER-2-directed therapy for advanced breast cancer;Verma;Oncologist,2013

3. Strategies and challenges for the next generation of antibody–drug conjugates;Beck;Nat Rev Drug Discov,2017

4. Ocular adverse events associated with antibody–drug conjugates in human clinical trials;Eaton;J Ocul Pharmacol Ther,2015

5. Trastuzumab-induced corneal ulceration: successful no-drug treatment of a “blind” side effect in a case report;Orlandi;BMC Cancer,2015

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in HER2-Targeted Therapies: From monoclonal antibodies to dual inhibitors developments in cancer treatment;Bioorganic Chemistry;2024-10

2. First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors;npj Precision Oncology;2024-09-12

3. HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial;Nature Communications;2024-06-17

4. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy;Frontiers in Immunology;2023-12-11

5. Ocular surface toxicities associated with modern anticancer therapies;Survey of Ophthalmology;2023-10